
On Friday 03/17/2023 the closing price of the Reviva Pharmaceuticals Holdings Inc Registered Shs share was $3.95 on NAS.
Compared to the opening price on Friday 03/17/2023 on NAS of $3.98, this is a drop of 0.76%.
Reviva Pharmaceuticals Holdings Inc Registered Shs's market capitalization is $81.81 M by 20.44 M shares outstanding.
Reviva Pharmaceuticals Holdings Stock Snapshot
3.96
Bid
200.00
Bid Size
4.00
Ask
300.00
Ask Size
3/17/2023
Date
8:00 PM
Time
23,122.00
Volume
4.10
Prev. Close
3.98
Open
81.81 M
Market Cap
20.44 M
Number of Shares
3.95
Day Low
4.10
Day High
3.95
0.53
52 Week Low
6.10
52 Week High
3.95
77.32
Free Float in %
-0.82
EPS 2023
Reviva Pharmaceuticals Holdings News More News
Reviva Pharmaceuticals Holdings Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Reviva Pharmaceuticals Holdings Analyst Data
Total Analysts: 4
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 10.00
Median: 10.00
Highest: 10.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Reviva Pharmaceuticals Holdings Analyst Opinions
- All
- Buy
- Hold
- Sell
| 01/25/23 | H.C. Wainwright & Co. | Maintained Buy | $10 | ||
| 11/01/22 | Maxim Group | Maintained Buy | $10 | ||
| 01/24/22 | H.C. Wainwright & Co. | Maintained Buy | $10 | ||
| 07/26/21 | Maxim Group | Maintained Buy | $10 |
Reviva Pharmaceuticals Holdings Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue | 0 | 0 | 132 | 154 |
| Dividend | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - |
| EPS | -0.82 | -0.88 | -1.09 | 1.37 |
| P/E Ratio | -4.80 | -4.51 | -3.62 | 2.88 |
| EBIT | -22 | -27 | -42 | 58 |
| EBITDA | - | - | - | - |
| Net Profit | -22 | -27 | -42 | 58 |
| Net Profit Adjusted | -26 | -29 | -32 | - |
| Pre-Tax Profit | -20 | -26 | -52 | 58 |
| Net Profit (Adjusted) | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - |
| EPS (GAAP) | -0.83 | -0.89 | -1.33 | 1.37 |
| Gross Income | - | - | 92 | 116 |
| Cash Flow from Investing | - | - | - | - |
| Cash Flow from Operations | -31 | -34 | -37 | - |
| Cash Flow from Financing | 47 | 49 | - | - |
| Cash Flow per Share | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - |
| Book Value per Share | - | - | - | - |
| Net Debt | - | - | - | - |
| Research & Development Exp. | 15 | 19 | 28 | 33 |
| Capital Expenditure | - | - | - | - |
| Selling, General & Admin. Exp. | 6 | 13 | 20 | 24 |
| Shareholder’s Equity | 30 | 44 | 7 | - |
| Total Assets | 35 | 50 | 13 | - |
| Previous Quarter | Current Quarter | Next Quarter |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 4 | 2 | 2 | 4 | 3 |
| Average Estimate | -0.220 USD | -0.235 USD | -0.215 USD | -0.823 USD | -0.877 USD |
| Year Ago | - | -0.400 USD | -0.290 USD | - | -0.823 USD |
| Publish Date | 3/20/2023 | 5/15/2023 | 8/14/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | - | - | 1 | 1 |
| Average Estimate | - | - | - | 0 USD | 0 USD |
| Year Ago | - | - | - | - | 0 USD |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Reviva Pharmaceuticals Holdings Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Patel Purav | 11/17/2022 | 3,000.00 | 43,547.00 | 4.69 | Buy | No |
| Narayan Prabhu | 09/29/2022 | 50,000.00 | 100,000.00 | 1.66 | Buy | No |
| Narayan Prabhu | 06/29/2022 | 50,000.00 | 50,000.00 | 1.21 | Buy | No |
| VEDANTA PARTNERS, LLC | 05/31/2021 | 399,000.00 | 399,000.00 | 3.75 | Buy | No |
| VEDANTA PARTNERS, LLC | 05/31/2021 | 931,000.00 | 931,000.00 | 3.75 | Buy | No |
| VEDANTA PARTNERS, LLC | 12/13/2020 | 197,500.00 | 2,121,750.00 | n/a | Buy | No |
| GLAZER PAUL J | 12/07/2020 | 367,000.00 | n/a | 10.88 | Sell | No |
| Hudson Bay Master Fund Ltd. | 12/07/2020 | 710,000.00 | n/a | 10.88 | Sell | No |
| Hudson Bay Master Fund Ltd. | 12/06/2020 | 50,000.00 | 710,000.00 | 11.51 | Sell | No |
| GLAZER PAUL J | 12/02/2020 | 606,360.00 | n/a | 10.88 | Sell | No |
| GLAZER PAUL J | 12/01/2020 | 261.00 | 606,360.00 | 11.00 | Sell | No |
| GLAZER PAUL J | 11/30/2020 | 5,362.00 | 606,621.00 | 11.00 | Sell | No |
| GLAZER PAUL J | 11/26/2020 | 5,969.00 | 611,983.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/23/2020 | 7,103.00 | 617,952.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/22/2020 | 23,611.00 | 625,055.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/17/2020 | 896.00 | 648,666.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/16/2020 | 127.00 | 649,562.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/15/2020 | 305.00 | 649,689.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/10/2020 | 5.00 | 649,994.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/05/2020 | 1.00 | 649,999.00 | 10.90 | Sell | No |
| GLAZER PAUL J | 11/02/2020 | 57,616.00 | 650,000.00 | 10.85 | Sell | No |
| GLAZER PAUL J | 11/01/2020 | 1.00 | 707,616.00 | 11.50 | Sell | No |
| Hudson Bay Master Fund Ltd. | 11/01/2020 | 50,000.00 | 760,000.00 | 10.87 | Sell | No |
| GLAZER PAUL J | 09/28/2020 | 2.00 | 707,617.00 | 11.50 | Sell | No |
| GLAZER PAUL J | 09/16/2020 | 1,000.00 | 707,619.00 | 10.80 | Sell | No |
Reviva Pharmaceuticals Holdings Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2021 | Reviva Pharmaceuticals Holdings Inc Registered Shs | - | - | USD |
| 2020 | Reviva Pharmaceuticals Holdings Inc Registered Shs | - | - | USD |
| 2019 | Reviva Pharmaceuticals Holdings Inc Registered Shs | - | - | USD |
*Yield of the Respective Date
Reviva Pharmaceuticals Holdings Inc Registered Shs Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.220 USD | Q4 2022 Earnings Release | 03/20/2023 |
| Earnings Report | -0.235 USD | Q1 2023 Earnings Release | 05/15/2023 |
| Earnings Report | -0.215 USD | Q2 2023 Earnings Release | 08/14/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 11/13/2023 |
Reviva Pharmaceuticals Holdings Profile
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded on December 11, 2020 and is headquartered in Cupertino, CA.
Reviva Pharmaceuticals Holdings Shareholder
| Owner | in % |
|---|---|
| Freefloat | 77.32 |
| Laxminarayan Bhat, PhD | 12.12 |
| Vedanta Capital LLC | 9.63 |
| Armistice Capital LLC | 3.46 |
| Rahul Nayar | 2.52 |
| Vanguard Group, Inc. (Subfiler) | 2.25 |
| Vanguard Total Stock Market Index Fund | 1.82 |
| Vanguard Extended Market Index Fund | 0.86 |
| Geode Capital Management LLC | 0.71 |
| EMC Capital Management LLC | 0.61 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.